B+
Bull case
25%
Probability
Target price
$3.20
+68.4% vs current
PROK
ProKidneyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$1.90
0.0% vs current
B-
Bear case
30%
Probability
Target price
$0.85
-55.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+49.3
Score
AI commentary
This was a T+3 post-earnings follow-up centered on company filings rather than broad news flow. The primary-source message was stable-to-slightly-positive on trial timing, but market reaction was muted: PROK closed at $1.66 on May 15, 2026, down about 2.9% on the day, and after-hours trading shown in secondary market data was essentially flat. Trusted secondary coverage indicated a modest EPS miss against consensus but a revenue beat, and no clear post-print analyst target-reset signal was available by 2026-05-16. With no social packet coverage and limited external revision evidence, sentiment remains cautious and monitoring-oriented rather than bullish.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventPROACT 1 accelerated-approval enrollment completionHigh impact
Management reiterated that PROACT 1 enrollment for the accelerated-approval efficacy analysis remains on track for mid-2026, which is the next concrete de-risking milestone for rilparencel and the main near-term proof that trial execution is holding. [#8-K-2026-05-15]
2027-06-30catalystRunway versus spend trajectory after Q1High impact
Q1 2026 cash, cash equivalents and marketable securities were $224.9 million, while management said this funds operations only into mid-2027; with R&D up to $33.8 million from $27.3 million on continued PROACT 1 activity, investors are likely to monitor whether execution stays on plan without pulling financing risk forward. [#10-Q-2026-05-15]
2027-06-30catalystQ2 2027 pivotal eGFR-slope topline readoutHigh impact
The company continues to guide to pivotal topline surrogate-endpoint results in Q2 2027, with FDA alignment that a 1.5 mL/min/1.73m2 annualized eGFR-slope effect size would be acceptable under the RMAT pathway; that keeps the stock primarily tethered to a binary clinical milestone rather than near-term revenue. [#8-K-2026-05-15]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology